-
1
المؤلفون: Lisa A. Hammond, Randall Johnson, Anthony W. Tolcher, John M. Lambert, Chris H. Takimoto, Helen Martino, Ravi V. J. Chari, Theresa Mays, Zdenka Ludmila Jonak, Johann S. de Bono, Amita Patnaik, Charlene Audette, Leonel Ochoa, Garry Schwartz, Kate Maes, Mark DeWitte, Lon Smith, Eric K. Rowinsky, Tam Edwards
المصدر: Journal of Clinical Oncology. 21:211-222
مصطلحات موضوعية: Adult, Male, Cancer Research, Immunoconjugates, Maximum Tolerated Dose, medicine.drug_class, medicine.medical_treatment, Pharmacology, Mertansine, Monoclonal antibody, Maytansinoid, chemistry.chemical_compound, Pharmacokinetics, Neoplasms, medicine, Humans, Maytansine, Infusions, Intravenous, Aged, Dose-Response Relationship, Drug, business.industry, Mucin-1, Antibodies, Monoclonal, Immunotherapy, Middle Aged, Cantuzumab mertansine, Antineoplastic Agents, Phytogenic, Immunoconjugate, Oncology, chemistry, Immunology, Monoclonal, Female, business, Half-Life, medicine.drug
URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a591334122ff29b3268f7b316978dbcb
https://doi.org/10.1200/jco.2003.05.137